Shattuck Labs, Inc. (STTK) Stock Price & Analysis
Shattuck Labs, Inc. (STTK) rose 4.80% to USD 7.43 as of July 25, 2026 at 05:45 UTC, according to Nexqual real-time market data.
STTK last closed at USD 7.09; the session ranged USD 6.96–7.5 on volume of 1,467,720 shares. Market capitalization is $709.63M, with a 52-week range of USD 0.71–8.33 (NMS). Source: Nexqual, July 25, 2026 at 05:45 UTC.
Key Statistics (as of July 25, 2026 at 05:45 UTC)
| Price | USD 7.43 |
|---|---|
| Change | ▲ 4.80% (up) |
| Previous Close | USD 7.09 |
| Open | USD 7.35 |
| Day Range | USD 6.96 – 7.5 |
| 52-Week Range | USD 0.71 – 8.33 |
| Volume | 1,467,720 shares |
| Market Cap | $709.63M |
| Exchange | NMS |
Technical Analysis (STTK)
Nexqual's technical model rates STTK "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 05:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.84 (neutral) |
| vs SMA50 | Above (USD 5.99) |
| MACD | 0.36 (positive) |
Analyst Ratings (STTK)
Wall Street analysts rate STTK "Strong Buy" based on 8 analysts, with a mean price target of USD 14.38 (range USD 10–18), per Nexqual as of July 25, 2026 at 05:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 14.38 |
| High Target | USD 18 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (STTK)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.13 ▲ beat |
| 2025-12-31 | USD -0.12 vs est -0.13 ▲ beat |
| 2025-09-30 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.24 vs est -0.25 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:45 UTC.
Financials & Fundamentals (STTK)
| Total Revenue | $1.00M |
|---|---|
| Gross Margin | -297.80% |
| Operating Margin | -5258.30% |
| Profit Margin | +0.00% |
| ROE | -61.04% |
| Debt / Equity | 3.02 |
| Current Ratio | 22.07 |
| Total Cash | $90.42M |
| Total Debt | $2.89M |
| Free Cash Flow | $-22.42M |
Source: Nexqual, July 25, 2026 at 05:45 UTC.
Financial Health Score (STTK)
Nexqual rates Shattuck Labs, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:45 UTC.
| Growth | Critical — Revenue -83% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $90M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$22M, burning cash |
| Efficiency | Critical — ROE -61%, ROA -36.7% |
Ownership (STTK)
| Insider Ownership | +4.53% |
|---|---|
| Institutional Ownership | +60.07% |
| Shares Outstanding | 95.51M |
| Float | 48.51M |
| Short % of Float | +8.48% |
Source: Nexqual, July 25, 2026 at 05:45 UTC.
Leadership (STTK)
Shattuck Labs, Inc. is led by Taylor H. Schreiber (age 45), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 05:45 UTC.
| Co-Founder, CEO & Director | Taylor H. Schreiber (age 45) |
|---|---|
| Chief Financial Officer | Andrew R. Neill (age 39) |
| Vice President of Accounting & SEC reporting | Brad Huckabee |
| Chief Scientific Officer | Suresh de Silva |
| Senior Vice President of Regulatory Affairs | Thomas Lampkin Pharm.D. |
Major Backers & Investors (STTK)
Notable institutional backers of Shattuck Labs, Inc. include T. Rowe Price, Orbimed Advisors LLC., Redmile Group, LLC, according to Nexqual as of July 25, 2026 at 05:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 22.43% |
| Orbimed Advisors LLC. | 8.22% |
| Redmile Group, LLC | 7.22% |
| Prosight Management, Lp | 6.53% |
| Adage Capital Partners GP L.L.C. | 6.06% |
| Price (T.Rowe) Associates Inc | 5.96% |
| Nextbio Capital Management LP | 4.11% |
| Clark Estates Inc. (The) | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.86% |
Source: Nexqual, July 25, 2026 at 05:45 UTC.
From Shattuck Labs, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property We strive to protect and enhance our proprietary technology, inventions, and improvements that we consider commercially important to the development of our business, including by seeking, maintaining, and defending U.S. and foreign patent rights, including patents covering our platform technologies, product candidates, and methods of using the same, whether developed internally or licensed from third parties.
- This agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
- We also rely on trade secrets, know-how, and continuing technological innovation to develop, strengthen and maintain our proprietary position in our field.
Partnerships
- Because DR3 is a membrane-restricted target, immune complex formation is not expected either for SL-325, SL-425, or DR3 directed bispecific antibodies. 7 Manufacturing and Supply By working with third-party vendors to conduct activities in compliance with current Good Manufacturing Practices ("cGMP"), we have invested significant resources to identify and scale up a suitable manufacturing process for our product candidates, including SL-325.
- We manufacture bulk drug substance ("BDS") for SL-325 utilizing the services of a single third-party contract manufacturer, Kemwell Biopharma Private Limited ("Kemwell"), with whom we maintain a master service agreement, pursuant to which Kemwell manufactures BDS on a per project basis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | USD 3.4 | ▼ 9.09% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.83 | ▼ 2.42% |
| FHTX | Foghorn Therapeutics Inc. | USD 4.85 | ▼ 6.91% |
| TSHA | Taysha Gene Therapies, Inc. | USD 5.52 | ▼ 2.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:45 UTC. This page is informational and not investment advice.